Pass RF - Search Results

1

Enzyme-linked immunosorbent assay for measurement of cytomegalovirus glycoprotein B antibody in serum.

Hackett DJ, Zhang C, Stefanescu C, Pass RF. Hackett DJ, et al. Among authors: pass rf. Clin Vaccine Immunol. 2010 May;17(5):836-9. doi: 10.1128/CVI.00422-09. Epub 2010 Mar 10. Clin Vaccine Immunol. 2010. PMID: 20219875 Free PMC article.

2

Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.

Zhang C, Pass RF. Zhang C, et al. Among authors: pass rf. Vaccine. 2004 Dec 9;23(4):507-10. doi: 10.1016/j.vaccine.2004.06.027. Vaccine. 2004. PMID: 15530699 Clinical Trial.

3

Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding.

Zhang C, Buchanan H, Andrews W, Evans A, Pass RF. Zhang C, et al. Among authors: pass rf. J Clin Virol. 2006 Mar;35(3):338-42. doi: 10.1016/j.jcv.2005.09.020. Epub 2006 Jan 4. J Clin Virol. 2006. PMID: 16388984 Clinical Trial.

4

Vaccine prevention of maternal cytomegalovirus infection.

Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G. Pass RF, et al. N Engl J Med. 2009 Mar 19;360(12):1191-9. doi: 10.1056/NEJMoa0804749. N Engl J Med. 2009. PMID: 19297572 Free PMC article. Clinical Trial.

5

Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.

Sabbaj S, Pass RF, Goepfert PA, Pichon S. Sabbaj S, et al. Among authors: pass rf. J Infect Dis. 2011 Jun 1;203(11):1534-41. doi: 10.1093/infdis/jir138. J Infect Dis. 2011. PMID: 21592981 Free PMC article.

6

Priorities for CMV vaccine development.

Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA, Ljungman P, Mocarski ES, Pass RF, Read JS, Schleiss MR, Plotkin SA. Krause PR, et al. Among authors: pass rf. Vaccine. 2013 Dec 17;32(1):4-10. doi: 10.1016/j.vaccine.2013.09.042. Epub 2013 Oct 13. Vaccine. 2013. PMID: 24129123 Free PMC article. Review.

7

Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans.

Jenks JA, Nelson CS, Roark HK, Goodwin ML, Pass RF, Bernstein DI, Walter EB, Edwards KM, Wang D, Fu TM, An Z, Chan C, Permar SR. Jenks JA, et al. Among authors: pass rf. Sci Transl Med. 2020 Nov 4;12(568):eabb3611. doi: 10.1126/scitranslmed.abb3611. Sci Transl Med. 2020. PMID: 33148624 Free PMC article.

8

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.

Pass RF, Duliegè AM, Boppana S, Sekulovich R, Percell S, Britt W, Burke RL. Pass RF, et al. J Infect Dis. 1999 Oct;180(4):970-5. doi: 10.1086/315022. J Infect Dis. 1999. PMID: 10479120 Clinical Trial.

9

Virus-specific antibody responses in mothers and their newborn infants with asymptomatic congenital cytomegalovirus infections.

Boppana SB, Pass RF, Britt WJ. Boppana SB, et al. Among authors: pass rf. J Infect Dis. 1993 Jan;167(1):72-7. doi: 10.1093/infdis/167.1.72. J Infect Dis. 1993. PMID: 8380292

10

Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.

Pass RF. Pass RF. J Clin Virol. 2009 Dec;46 Suppl 4(Suppl 4):S73-6. doi: 10.1016/j.jcv.2009.07.002. Epub 2009 Jul 31. J Clin Virol. 2009. PMID: 19647480 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

183 results

Search Page

Filters